Friday, 21 January 2011

Doctors criticise leukaemia drug study into MabThera (also known as rituximab).


Three Australian oncologists say cancer treatment research published in one of the world's most prestigious medical journals may have been compromised by a drug company that funded the study.

They said publication of the research in The Lancet might have boosted the drug's perceived value to doctors and patients around the world, helping its manufacturer, Roche, make billions of dollars from the product.

To read the full story click HERE.

No comments: